Farshidpour M, Ahmed M, Junna S, Merchant JL. Myeloid-derived suppressor cells in gastrointestinal cancers: A systemic review. World J Gastrointest Oncol 2021; 13(1): 1-11 [PMID: 33510845 DOI: 10.4251/wjgo.v13.i1.1]
Corresponding Author of This Article
Maham Farshidpour, MD, Doctor, Inpatient Medicine, Banner University of Medical Center, 1501 N Campbell Ave, Tucson, AZ 85724, United States. mfarshidpour@email.arizona.edu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Therapeutic and Diagnostic Guidelines
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Jan 15, 2021; 13(1): 1-11 Published online Jan 15, 2021. doi: 10.4251/wjgo.v13.i1.1
Myeloid-derived suppressor cells in gastrointestinal cancers: A systemic review
Maham Farshidpour, Monjur Ahmed, Shilpa Junna, Juanita L Merchant
Maham Farshidpour, Inpatient Medicine, Banner University of Medical Center, Tucson, AZ 85724, United States
Monjur Ahmed, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA 19107, United States
Shilpa Junna, Juanita L Merchant, Division of Gastroenterology and Hepatology, Banner University of Medical Center, Tucson, AZ 85724, United States
Author contributions: Farshidpour M and Merchant JL conceived of and designed the study, and collected the data; Farshidpour M, Ahmed M, Junna S, and Merchant JL drafted the manuscript; all authors reviewed the results and approved the final version of the manuscript.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Maham Farshidpour, MD, Doctor, Inpatient Medicine, Banner University of Medical Center, 1501 N Campbell Ave, Tucson, AZ 85724, United States. mfarshidpour@email.arizona.edu
Received: August 25, 2020 Peer-review started: August 25, 2020 First decision: November 16, 2020 Revised: December 1, 2020 Accepted: December 16, 2020 Article in press: December 16, 2020 Published online: January 15, 2021 Processing time: 130 Days and 16.3 Hours
Abstract
Gastrointestinal (GI) cancers are one of the most common malignancies worldwide, with high rates of morbidity and mortality. Myeloid-derived suppressor cells (MDSCs) are major components of the tumor microenvironment (TME). MDSCs facilitate the transformation of premalignant cells and play roles in tumor growth and metastasis. Moreover, in patients with GI malignancies, MDSCs can lead to the suppression of T cells and natural killer cells. Accordingly, a better understanding of the role and mechanism of action of MDSCs in the TME will aid in the development of novel immune-targeted therapies.
Core Tip: In patients with cancer, the levels of myeloid-derived suppressor cells (MDSCs) are presumed to be of prognostic and predictive value. Recent studies have shown that MDSCs appear to be independent prognostic factors in gastrointestinal cancer. In addition, therapeutics that target MDSCs have been shown to enhance anti-tumor immune responses in animal models. Consequently, a better understanding of the role and mechanism of action of MDSCs in the tumor microenvironment may aid in the development of novel immune-targeted therapies.
